Bortezomib (PS-341)

Catalog No.S1013 Synonyms: LDP-341, MLM341

Bortezomib (PS-341) Chemical Structure

Molecular Weight(MW): 384.24

Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.

Size Price Stock Quantity  
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 142 Publications

20 Customer Reviews

  • Effect of different proteasome inhibitors on dysferlin expression and on membrane resealing in cultured primary myoblasts. Primary myoblasts from patient 2 harboring a homozygous Arg555Trp DYSF mutation that were treated with the indicated amounts of bortezomib for 24 hours. Western blots of protein extracts were stained with anti-dysferlin antibodies and with anti–a-tubulin antibody as loading control.

    Sci Transl Med 2015 6(250), 250ra112. Bortezomib (PS-341) purchased from Selleck.

    Pharmacologic inhibition of the proteasome blocks proplatelet formation in murine and human megakaryocytes. Human megakaryocytes were pretreated with vehicle or bortezomib, and megakaryocytes producing proplatelets (PP) were examined. Shown are representative transmission images and representative confocal images with wheat germ agglutinin (WGA; red) and phalloidin (green) staining. Scale bars: 50 um.

    J Clin Invest 2014 124(9), 3757-66. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence showing HDAC4 localization in mouse primary osteoblasts treated with vehicle or PTH alone or in the presence of bortezomib. Primary osteoblasts treated with vehicle, PTH, or PTH plus bortezomib for 2 h using anti-HDAC4 and anti-b-actin antibodies.

    J Cell Biol 2014 205(6), 771-80. Bortezomib (PS-341) purchased from Selleck.

    Effects of NF-kB inhibition on cell proliferation and apoptosis in Foxp3cKO prostate. A. Top left panels: Representative H&E staining of PIN lesions in ventral prostates of 60-week-old PBS- or bortezomib-treated Foxp3cKO littermates. Scale bar, 50 祄. Right graph: Quantification of Ki67-positive cells identified by IHC analysis (bottom left panels) as a measure of cell proliferation, performed with Scion Image software. Horizontal lines represent the average values. The p value was determined by two-tailed t test. B. Representative western blots showing p65 and nuclear p65 (N-p65) expression in prostates at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. C. Quantification of Bcl2l1 and Traf1/2 mRNA expression as a percentage of Hprt expression measured in microdissected mouse prostate epithelial cells by qPCR at 12 hours after LPS injection in 45-week-old PBS- or bortezomib-treated mice. Horizontal lines represent the average values. The p values were determined by two-tailed t test. D. Left panels: Representative images of TUNEL assays performed on prostates from PBS- or bortezomib-treated mice at 60 weeks of age. Insets show the apoptotic cells (green) in prostate glands. Scale bar, 100 祄. Right graph: Quantification of apoptotic cells in the ventral and dorsolateral prostates of PBS- or bortezomib-treated mice at 45 and 60 weeks of age. Horizontal lines represent the average values. The p value was determined by two-tailed t test. cKO, PB4-Cre4+Foxp3flox/y; wks, weeks; B/P, ratio of the mean value from bortezomib-treated mice to the mean value in PBS-treated mice. All experiments were repeated two times. Wks, weeks.

    Cancer Res 2015 75(8), 1714-24. Bortezomib (PS-341) purchased from Selleck.

  • Inhibition of proteasome and lysosome or silencing of VCP and co-factors lead to the accumulation of OP-puro-labeled DRIPs adjacent to or within SGs. HeLa cells were co-treated for 45 min with OP-puro and arsenite (Ars.); where indicated, cells were pretreated with bortezomib (Bort.) overnight and/or ammonium chloride (NH4Cl) for 2 h 15 min. Cells were fixed and labeled with Alexa594-Azide and anti-TIA-1.

    Cell Death Differ 2014 21(12), 1838-51. Bortezomib (PS-341) purchased from Selleck.

    Control wild-type and Fmn2–/–oocytes observed at different stages of meiotic maturation [prophase I (Pro I), NEBD, 3 hours and 8 hours after NEBD] using anti-Fmn2. wt + Bortezo, wild-type oocytes treated with 0.1μM Bortezomib for 90 minutes before fixation. All oocytes were observed using the same settings and the images treated the same way (three independent experiments). Red arrows indicate cortical labeling. Scale bar: 10μm.

    Development 2011 138, 2903-2908. Bortezomib (PS-341) purchased from Selleck.

  • Immunofluorescence analysis for Ser536 p-NF-κB cellular localization of RS4;11cells treated with CX-4945 (5 μM) and bortezomib (2.5 nM) either alone or in combination. Cells were treated, collected at 22 h and reacted with an antibody to Ser536 p-NF-κB which was revealed by a Cy3-conjugated secondary antibody. DAPI was used to label nuclei.

    Oncotarget, 2015, 51: S659-S660. Bortezomib (PS-341) purchased from Selleck.

    (B–C) LNCaP (B) and LNCaP-AI (C) cells were transiently transfected with sPLA2-IIa(-800)-Luc (0.5 μg). The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) without or with EGF (100 ng/ml) for 24 h. Luciferase assay was performed according to a standard protocol with Renilla luciferase as an internal control. Data are presented as the mean (±SD) of duplicate values of a representative experiment that was independently repeated for five times.

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

  • LNCaP-AI cells were starved in 1% stripped medium for 24 h. The cells were then treated with Erlotinib (20 μM), Gefitinib (20 μM), Lapatinib (20 μM), CI-1033 (8 μM), LY294002 (20 μM) and Bortezomib (20 μM) for 24 h. Cell culture medium was collected from each sample and subjected to ELISA for sPLA2-IIa. The condition medium samples were diluted 10 times for ELISA. Average of duplicate samples was converted to nanogram per milliliter against standard curve. The data represent one of five repeated experiments.

     

     

    Carcinogenesis 2010 31, 1948–1955. Bortezomib (PS-341) purchased from Selleck.

    The stable cell line HepAD38 was incubated for 18 h in the presence of the indicated amount of Bortezomib. The medium was removed and replaced by medium containing Bortezomib dissolved in PBS. In case of the control cells the same amount of PBS was added to the medium. 4 h later this procedure was repeated and again 14 h later the supernatant was collected. The amount of viral particles was quantified by real time PCR. HBV-genome quantification was done using COBAS® AmpliPrep/COBAS® TaqMan® HBV test (Roche Diagnostics GmbH, Mannheim, Germany) according to the manufacturer’s instructions. The assay shows relative values (the value for untreated control cells was arbitrarily set as 1) that are based on three independent experiments. The cell viability was analyzed by MTT assays. For does up to 50 nM no significant effect on cell viability was observed within 18h, for 100 nM the proportion of metabolically active cells was reduced to 83%.

    J Biol Chem 2010 285, 41074-41086. Bortezomib (PS-341) purchased from Selleck.

  • Western blot of extracts of infected cells treated with different proteasome inhibitors at different concentrations, reacted with the indicated antibodies. p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Time window treatment with proteasome inhibitors. (A) Scheme of the experiment performed with MA104 cells exposed to virus (OSU; MOI, 3) for 1 h and analyzed at the starting point and endpoint of the indicated time window treatments with DMSO, MG132, or bortezomib. (B) Western blot of cellular lysates derived from cells infected for the indicated time periods and treated with the proteasome inhibitors or DMSO. NI, noninfected cells. Blots were reacted with the indicated antibodies; p53 was used to monitor proteasome inhibition, and actin was used as a loading control.

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • Fluorescence analysis of viroplasm formation on NSP5-EGFP cells infected with rotavirus (OSU; MOI, 3) and treated or not treated with MG132 (10 M) or bortezomib (10 M) at different times p.i., as indicated. Cells were analyzed at the starting points (1 h, 3 h, 5 h, 7 h) and endpoints (9 h) of the inhibitor’s window treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

    Quantification of the accumulation of viroplasms in infected NSP5 -EGFP/MA104 cells. At different times p.i., cells were treated for 4 h with DMSO or the indicated proteasome inhibitor and the number of viroplasms/cell was quantified at the starting (1 h, 3 h, 5 h; white bars) and endpoints (5 h, 7 h, 9 h) of treatment.

     

     

    J Virol 2011 85, 2781–2792. Bortezomib (PS-341) purchased from Selleck.

  • PS-341 impairs FPV replication in A549 cells. (A and B)A549 cells were either pretreated for 1 h with different concentrations of PS-341 or with solvent only or were left untreated. Then, cells were infected with FPV at an MOI of 0.001 (A) or 0.05 (B). After virus inoculation cells were posttreated with different concentrations of PS-341. (A) At 24 h p.i. supernatants were obtained and progeny virus titers were measured by standard plaque assay. (B)Proteasome activity and the ability of PS-341 to inhibit the proteasome was determined 24 h p.i. (C) A549 cells were pretreated with 50 nM PS-341 or solvent or left untreated for 1 h. Afterwards cells were infected with FPV at an MOI of 0.0005. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or solvent or left untreated. After the indicated times p.i.supernatants were obtained and progeny virus titers were determined by standard plaque assay. Arrow bars in all experiments represent standard deviations of three independent experiments.

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Early steps of viral replication within the first replication cycle are affected. (A) For time-of-addition kinetics analysis, A549 cells were either left untreated or were pretreated for 10 h or 1 h with 50 nM PS-341 before infection and additionally posttreated after infection. Cells were infected with FPV at an MOI of 0.005. After virus inoculation cells were posttreated with 50 nM PS-341. Then the proteasome inhibitor was added after virus inoculation (10 h, 1 h, and 30 min) or it was added at the different times p.i. as indicated (1 h, 2 h, 4 h, 6 h, and 8 h; cells were not pretreated before infection). At 9 h p.i. supernatants were obtained and progeny virus titers were determined by standard plaque assay. Shown is one representative experiment out of three independent experiments. (B) A549 cells were pretreated with 50 nM PS-341 or left untreated for 1 h. Afterwards cells were infected with avian FPV or human PR8 at an MOI of 1. Subsequent to virus inoculation cells were posttreated with 50 nM PS-341 or left untreated. After the indicated times p.i. cells were lysed and analyzed by Western blotting for accumulation of viral proteins polymerase PB1 and matrix protein M1. Cellular protein ERK2 served as a control to demonstrate equal amounts of protein loading. Shown is one representative blot out of three independent experiments.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

  • A549 cells were treated with PS-341 at 50 nM for the indicated times or left untreated. Western blotting was performed with total cell lysates, using phospho-specific antibodies against JNK and the transcription factors c-Jun and ATF-2 or loading controls, respectively.

     

     

    J Virol 2010 84, 9439–9451. Bortezomib (PS-341) purchased from Selleck.

    Proteasome inhibition effect on biotinylation of MHC-Iα. (a) WB-ra of cellular extracts of HEK293 cells co-transfected with BAP-MHC-Ia and cyt-BirA (control) and, where indicated, with US2 or US11 in the absence (2) or presence of MG132 (MG; 50 μM for 4 h) or Bortezomib(Bort.; 50 μM for 4 h).

    PLoS One 2011 6, e23712. Bortezomib (PS-341) purchased from Selleck.

  •  

    KKU-M213 was treated with BTZ as indicated. Total cell lysate ( a) and nuclear extract (b) were prepared. Actin and γ -tubulin were loading controls for total and nuclear proteins, respectively.

    2011 Mireia Vila Gasull University of Porto. Bortezomib (PS-341) purchased from Selleck.

    Mireia Vila Gasull University of Porto. 2011;Mireia Vila Gasull . Bortezomib (PS-341) purchased from Selleck.

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Bortezomib (PS-341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM in a cell-free assay.
Targets
20S proteasome [1]
(Cell-free assay)
0.6 nM(Ki)
In vitro

Bortezomib, a boronic acid dipeptide, is a highly selective, reversible inhibitor of the 26S proteasome which primarily functions in the degradation of mis-folded proteins and is essential for the regulation of the cell cycle. Exposure to Bortezomib has been shown to stabilize p21, p27, and p53, as well as the proapoptotic Bid and Bax proteins, caveolin-1, and inhibitor κB-α, which prevents activation of nuclear factor κB-induced cell survival pathways. Bortezomib also promotes the activation of the proapoptotic c-Jun-NH2 terminal kinase, as well as the endoplasmic reticulum stress response. Alteration of the levels of these cellular proteins leads to inhibition of proliferation, migration, and promotion of apoptosis of cancer cells. [2] Bortezomib is shown to penetrate into cells and inhibit proteasome-mediated intracellular proteolysis of long-lived proteins with a concentration that inhibits 50% of the proteolysis of ∼0.1 μM. The average growth inhibition of 50% value for Bortezomib across the entire panel of 60 cancer cell lines derived from multiple human tumors from the US National Cancer Institute (NCI) is 7 nM. Treatment of PC-3 cells with Bortezomib (100 nM) for 8 h results in the accumulation of cells in G2-M, with a corresponding decrease in the number of cells in G1. Bortezomib kills PC-3 cells at 24 and 48 hr with IC50 of 100 and 20 nM, respectively. Bortezomib induces nuclear condensation at 16–24 hr after treatment. Bortezomib treatment leads to PARP cleavage in a time-dependent manner with concentrations as low as 100 nM being effective at 24 hr. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF-7 MmD1R5l1d3SxeHnjJGF{e2G7 M3LvfVUxKM7:TR?= NGXBOpI1QCCq NGDHTodFVVOR MlfXT4ltdHNiY3XscJMh[nlibX;y[UB1cGGwIEm5KS=> MYmxNFQ6QTZ2Mx?=
OVCA 429 NHv1dIVHfW6ldHnvckBCe3OjeR?= NHHnWoo{ODBibl2= M{flXlQ5KGh? NXfsUoVNTE2VTx?= MUXEbZNzfXC2czDpcpRi[3RibYXseIlk\WyudXzhdkB1fW2xcjDzdIhmem:rZIO= MYqxNFk6QTd4Nh?=
RPMI8226 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jDUVExOCCwTR?= MYC0PEBp NICyZZFFVVOR MmrrTWM2OD1|MDDuUS=> MWCxNVMxPjR6OR?=
Dox40 M4THPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnnc5ROOTByIH7N MoXtOFghcA>? NH7QfGVFVVOR MXXJR|UxRTRyIH7N M{\vO|EyOzB4NEi5
MR20 MoDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV:xNFAhdk1? MUC0PEBp M2HmdmROW09? NX3welFMUUN3ME2yNEBvVQ>? M3vJSlEyOzB4NEi5
LR5 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDONVAxKG6P NUL0TlVIPDhiaB?= M2fqZmROW09? MXXJR|UxRTJyIH7N NYXjOlg1OTF|ME[0PFk>
U266 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fyeFExOCCwTR?= MX[0PEBp MWfEUXNQ NYH6WWxGUUN3ME2zJI5O NX;QeJdOOTF|ME[0PFk>
IM-9 M{jGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHkNVAxKG6P Ml\sOFghcA>? NFzBNZJFVVOR MlTlTWM2OD14IH7N NWXlbFd{OTF|ME[0PFk>
Hs Sultan NXTPfoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHXVmhmOTByIH7N MWe0PEBp MWHEUXNQ M1LX[GlEPTB;MkCgcm0> MUGxNVMxPjR6OR?=
PAM-LY2 MYHGeY5kfGmxbjDBd5NigQ>? MYixNFAhdk1? NFLkb28yOiCq M{Dwd2ROW09? NILZdllKdmirYnn0d{BPTi4QulKgZYN1cX[jdHnvci=> M4XNSFEyOzVyOUGz
PAM 212 MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLHTpUyODBibl2= M2jGNlczKGh? NFXvWlVFVVOR M3ft[GlvcGmkaYTzJINmdGxidnnhZoltcXS7 NWXQOHZuOTF|NUC5NVM>
PAM-LY2 M3vCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzDc24xOTByIH7N NX;We3loPzJiaB?= MXTEUXNQ MXnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MoXNNVE{PTB7MUO=
B4B8 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS0fGMyODBibl2= M2roOFczKGh? MkL1SG1UVw>? MXLJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MXKxNVM2ODlzMx?=
B7E3 MojZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxNFAhdk1? MU[3NkBp MYfEUXNQ M1G2UmlvcGmkaYTzJINmdGxidnnhZoltcXS7 MkXkNVE{PTB7MUO=
UM-SCC-9 NYLn[3g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqxNFAhdk1? MYO3NkBp NXjaZotTTE2VTx?= M1P1WmlvcGmkaYTzJINmdGxidnnhZoltcXS7 NWfWdZRMOTF|NUC5NVM>
UM-SCC-11B NV;vbJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu5e4ZbOTByIH7N NV:5NHc5PzJiaB?= MornSG1UVw>? M4G0Z2lvcGmkaYTzJINmdGxidnnhZoltcXS7 MlXQNVE{PTB7MUO=
H460 NGDHcolHfW6ldHnvckBCe3OjeR?= MlPBNVAh|ryP M{nVNFI1KGh? NVjvb4xoTE2VTx?= NWHKdW9nUW6mdXPld{BD[2xvMjDwbI9{eGixconsZZRqd25iYX7kJINt\WG4YXflJINwenKnbHH0[YQhf2m2aDDHNk1OKHCqYYPlJIFzemW|dB?= MUOxNlQ6OjFzNx?=
U266 NHXLWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXW1NFAhdmdxbXy= MWW0PEBp MoHrSG1UVw>? MUXJcohq[mm2czDj[YxtKGe{b4f0bC=> Mn;4NVI3OzF4MUm=
ARH77 Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z6U|UxOCCwZz;tcC=> MkfFOFghcA>? MVHEUXNQ NIrUblVKdmirYnn0d{Bk\WyuIHfyc5d1cA>? MojXNVI3OzF4MUm=
WAD-1 NYn3d|VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLTT442ODBibnevcYw> NYrCbJRvPDhiaB?= MlvUSG1UVw>? MWPJcohq[mm2czDj[YxtKGe{b4f0bC=> NEHmS4gyOjZ|MU[xPS=>
U266/LR7 MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXi1NFAhdmdxbXy= MkPvOFghcA>? MVLEUXNQ NV\j[|B4UW6qaXLpeJMh[2WubDDndo94fGh? NVLQNWN7OTJ4M{G2NVk>
U266/dox4 MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[1OVAxKG6pL33s Mly4OFghcA>? M{fhfGROW09? MXjJcohq[mm2czDj[YxtKGe{b4f0bC=> MYWxNlY{OTZzOR?=
RPMI8226/LR5 NYLPUHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7jZ2M2ODBibnevcYw> MlP2OFghcA>? MWfEUXNQ NX7rVmlJUW6qaXLpeJMh[2WubDDndo94fGh? NGfuRY0yOjZ|MU[xPS=>
H460 NFLMcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L0WVExKM7:TR?= M3jVVlczKGh? MXvEUXNQ NGDlS|hKSzVyPUGwNEBvVQ>? MmfoNVI3OzF4MkC=
H358 M2nJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVixNEDPxE1? NXHheVNTPzJiaB?= M1rrOmROW09? MVnJR|UxRTdyIH7N MlvWNVI3OzF4MkC=
H322 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;QSFExKM7:TR?= M{fFPFczKGh? MWXEUXNQ NF7jb4xKSzVyPU[yNEBvVQ>? MU[xNlY{OTZ{MB?=
H460 MXTGeY5kfGmxbjDBd5NigQ>? M2XVfFExOCCwTR?= MnnFNlQhcA>? NFLvNIlFVVOR MWTJcoR2[2W|IFeyMW0ueGijc3WgZZJz\XO2IHHu[EB1fWK3bHnuJIF{e2WvYnz5MYRqe2G|c3XtZox6 NHXJO2gyOjZ|MU[yNC=>
LNCap-Pro5 M4[zcGZ2dmO2aX;uJGF{e2G7 NWLvdFFoOSEQvF2= M1fHSlQhcA>? MV3EUXNQ MWfTeIFjcWyrenXzJJA2Ow>? NETWZmgyPDZzMkWzNi=>
T29 MVHBdI9xfG:|aYOgRZN{[Xl? MVK1NEBvVQ>? MmDiOFghcCB? MmK3SG1UVw>? MUjJcoR2[2W|IHPlcIwh[XCxcITvd4l{ NIHFZW4yPjd5OEG3PS=>
T29Kt1 NVLQdXh1SXCxcITvd4l{KEG|c3H5 MXq1NEBvVQ>? M3r4clQ5KGhi MUTEUXNQ NIHBToxKdmS3Y3XzJINmdGxiYYDvdJRwe2m| Mlq2NVY4PzhzN{m=
HCT116 MlnvRZBweHSxc3nzJGF{e2G7 NGnnWGM2OCCwTR?= M2PybVQ5KGhi M{D3TWROW09? M{LwUGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NG\pVnoyPjd5OEG3PS=>
HKe-3 MVHBdI9xfG:|aYOgRZN{[Xl? Ml3vOVAhdk1? NF;IO4s1QCCqIB?= M1LwSmROW09? MmSyTY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? Mn30NVY4PzhzN{m=
NB-1691 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\xdWdqOSEQvF2= MXi3NkBp M2DqSWlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyB3JR?= NHfWSnAyPzZ6OU[4OC=>
CHLA-255 MoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr0TW4yKM7:TR?= MXK3NkBp NYnofYhoUW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKHSxIEKl NFLWb4MyPzZ6OU[4OC=>
SK-N-AS NYrZbI1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvNTngyKM7:TR?= M{j6Z|czKGh? M3XjfmlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckB1dyBzMDW= MXKxO|Y5QTZ6NB?=
NB-1691 Mn70SpVv[3Srb36gRZN{[Xl? NF;yVnAyOCCwTR?= NUn0TpB7OjRiaB?= M4fzS3Nq\26rZnnjZY51dHlicnXkeYNmeyClZXzsd{BqdiC2aHWgS|AwTzFicHjhd4U> NX7uPIxYOTd4OEm2PFQ>
CHLA-255 MWLGeY5kfGmxbjDBd5NigQ>? MlXTNVAhdk1? NW\ESGg4OjRiaB?= NX;VcYYzVW:mZYP0cJkhemWmdXPld{Bk\WyuczDpckB1cGViR{CvS|EheGijc3W= NH3ubZoyPzZ6OU[4OC=>
RPMI 8226 NV7HPY5QTnWwY4Tpc44hSXO|YYm= M1\vOFIxKG6P NVzON2xiQCCq M2\ib3Nq\26rZnnjZY51dHliZX7oZY5k\XNiTl[t{tpDKGGldHn2bZR6 NGrieZkyQTR|NkC1NC=>
MM.1S NGK0ZYZHfW6ldHnvckBCe3OjeR?= NIHRVGkzOCCwTR?= M2LVeFghcA>? NFTIV3JUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? NYXyPWM1OTl2M{[wOVA>
U266 M2PMWGZ2dmO2aX;uJGF{e2G7 NUH3dZN[OjBibl2= M4W0UFghcA>? NUPTNWJTW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? M4G5c|E6PDN4MEWw
OPM1 MljySpVv[3Srb36gRZN{[Xl? NWiy[WZWOjBibl2= MVu4JIg> MoXHV4lodmmoaXPhcpRtgSCnbnjhcoNmeyCQRj5OvmIh[WO2aY\peJk> M{H0NVE6PDN4MEWw
INA6 NVO3cWVtTnWwY4Tpc44hSXO|YYm= M1TCPVIxKG6P MV[4JIg> NW\lNZVxW2mpbnnmbYNidnSueTDlcohidmOnczDOSk3PwkJiYXP0bZZqfHl? NVrmS2R[OTl2M{[wOVA>
OPM2 M3fmO2Z2dmO2aX;uJGF{e2G7 M2nOdFIxKG6P NVzaXnIyQCCq NFmzOJJUcWewaX\pZ4FvfGy7IHXubIFv[2W|IF7GMe67SiCjY4Tpeol1gQ>? M3zMN|E6PDN4MEWw
RPMI 8226 NWTQcYFjTnWwY4Tpc44hSXO|YYm= MXyyNEBvVQ>? NGHYU4s5KGh? M17kVWlv\HWlZYOgSG5CKHO7boTo[ZNqew>? M{nub|E6PDN4MEWw
BaF/3 MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYmxNFAhdk1? NGXrfZE1QCCq MUnJR|UxRTZwMjDuUS=> MljmNlA{ODV4OUK=
BaF/3-p210 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxNFAhdk1? NHH6fFI1QCCq M3X3NWlEPTB;ND63JI5O NEj2eVAzODNyNU[5Ni=>
TCC-S MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHTUYZUOTByIH7N M1roOlQ5KGh? NVzXeJg4UUN3ME2yMlghdk1? MlPUNlA{ODV4OUK=
BaF/3 M3HhUGZ2dmO2aX;uJGF{e2G7 NH:5PI43KG6P MVG0PEBp MmHlTY5lfWOnczDhJIdz\WG2IFexJINmdGxvY4njcIUh[XK{ZYP0 NXPhXYFnOjB|MEW2PVI>
BaF/3-p210 NGrLdIRHfW6ldHnvckBCe3OjeR?= MV62JI5O NE\3c3k1QCCq NEPVUZVKdmS3Y3XzJIEhe2yrZ3j0JGcyKGOnbHytZ5lkdGViYYLy[ZN1 NVfsXGFUOjB|MEW2PVI>
BaF/3-p210 M1vkUGZ2dmO2aX;uJGF{e2G7 NF7WcJE3KG6P NVXaS|Q6OjRiaB?= NYXRNYdZWmWmdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKGGwZDD0bIUh[WO2aY\peJkhd2ZiUnK= NWjjWoRKOjB|MEW2PVI>
Raji M2rtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrxNUDPxE1? MVOyOEBp NXKzSpdPWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg NIHEcnUzOTF5MEm4PC=>
LCL-1 NVnrdld{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY[xJO69VQ>? M{G2UVI1KGh? MmrHVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MYqyNVE4ODl6OB?=
LCL-2 NGLhZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDFNUDPxE1? M2XQ[lI1KGh? NFKyWVhT\WS3Y3XzJINmdGxidnnhZoltcXS7wrC= MmfpNlEyPzB7OEi=
BJAB MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q2RVEh|ryP MXqyOEBp M{jLbHJm\HWlZYOgZ4VtdCC4aXHibYxqfHoEoB?= M1Py[VIyOTdyOUi4
SNT-13 NF73OnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHUOGJmOSEQvF2= NU\T[FRSOjRiaB?= NWnXNXBRWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MXKyNVE4ODl6OB?=
SNT-16 NUTHSIVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITZfIwyKM7:TR?= MknrNlQhcA>? NWXRboZMWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg M{HQRVIyOTdyOUi4
Jurkat MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUCxJO69VQ>? Mn\zNlQhcA>? MWrS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MonwNlEyPzB7OEi=
KAI-3 M2fJ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXKxJO69VQ>? M3OwZlI1KGh? MmT0VoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi MWqyNVE4ODl6OB?=
SNK-6 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY[xJO69VQ>? NFnhN3AzPCCq MoraVoVlfWOnczDj[YxtKH[rYXLpcIl1gcLi NIq2OmMzOTF5MEm4PC=>
KHYG-1 M{i5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW4Z3VkOSEQvF2= MVmyOEBp MVvS[YR2[2W|IHPlcIwhfmmjYnnsbZR6yqB? MViyNVE4ODl6OB?=
SNT-16 NVzlcm13SXCxcITvd4l{KEG|c3H5 M2Hzd|Eh|ryP MlPnOkBp MXnJcoR2[2W|IHPlcIwh[XCxcITvd4l{ MoPINlEyPzB7OEi=
Jurkat NX\Fc483SXCxcITvd4l{KEG|c3H5 M3HKVFEh|ryP NFmyTZQ3KGh? NHjnT3BKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NGix[o0zOTF5MEm4PC=>
KAI-3 NHjLb41CeG:ydH;zbZMhSXO|YYm= M3T0PVEh|ryP NGPGZlU3KGh? M4XUbGlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NVqzU4dSOjFzN{C5PFg>
KHYG-1 NGjlcoxCeG:ydH;zbZMhSXO|YYm= M{nGdVEh|ryP MX22JIg> Mlq4TY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NGn0ZoQzOTF5MEm4PC=>
SNT-13 MWnBcpRqfmm{YXygRZN{[Xl? NHHxXogyKM7:TR?= MnnlNlQhcA>? NH7zXZdKdmS3Y3XzJIx6fGmlIHnu[oVkfGmxbjDv[kBGSlZ? NFzjc3QzOTF5MEm4PC=>
SNT-16 M1zZXmFvfGm4aYLhcEBCe3OjeR?= NVjrbms2OSEQvF2= NVzHTZE4OjRiaB?= M3L6Nmlv\HWlZYOgcJl1cWNiaX7m[YN1cW:wIH;mJGVDXg>? NYPXdHNlOjFzN{C5PFg>
KAI-3 M1y5e2FvfGm4aYLhcEBCe3OjeR?= M3v1clEh|ryP MXWyOEBp MYjJcoR2[2W|IHz5eIlkKGmwZnXjeIlwdiCxZjDFRnY> NYTJT4lWOjFzN{C5PFg>
SNK-6 MnXxRY51cX[rcnHsJGF{e2G7 MVOxJO69VQ>? MWqyOEBp NVnr[pdoUW6mdXPld{BtgXSrYzDpcoZm[3Srb36gc4YhTUKY MoHhNlEyPzB7OEi=
RAW 264.7 NGTxfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDyNVAxKG6P M4XtTVQ5KGh? NWi2SXZOWmWmdXPld{Bk\WyuII\pZYJqdGm2edMg MojsNlI1OjdzNUS=
A375 MnjjRZBweHSxc3nzJGF{e2G7 NHXmfnEyOCCwTR?= NHexb4UzPCCq NGeyOYdKdmS3Y3XzJINmdGxiYYDvdJRwe2m| NWfJfHB3OjNyN{mwPFM>
BLM Mli2RZBweHSxc3nzJGF{e2G7 NFfmV3MyOCCwTR?= NHzZSWUzPCCq M37sWmlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NIn0W5EzOzB5OUC4Ny=>
A375 MV7BeZRweGijZ4mgRZN{[Xl? MV[xNEBvVQ>? Mn:xNVIhcA>? NEfQenJKdmS3Y3XzJIZwem2jdHnvckBw\iCjdYTvdIhi\2:|b33ldy=> MXiyN|A4QTB6Mx?=
BLM MlKxRZV1d3CqYXf5JGF{e2G7 MkX4NVAhdk1? NGWwZVEyOiCq NVzwO4dQUW6mdXPld{Bnd3KvYYTpc44hd2ZiYYX0c5Bp[Wexc3;t[ZM> NIO5NWczOzB5OUC4Ny=>
H1299 NVy0WpBPSXCxcITvd4l{KEG|c3H5 NITKXYY5OCCwTR?= MkDGNlQhcA>? NWnDfXZzTE2VTx?= MXjT[Y5{cXSrenXzJG5US0yFIHPlcIx{KHSxIF3TR{1l\XKrdnXkJIlEQS2rbnT1Z4VlKGGyb4D0c5Nqew>? M1i1SVI2OzJ|Nkmz
Hut-78 NWDPbGprTnWwY4Tpc44hSXO|YYm= M131SlExOCCwTR?= M{WzXlI1KGh? MYfEUXNQ MmDTSI94dnKnZ4XsZZRmeyCWR1[t{tIyKGGwZDDJUE0yOCCneIDy[ZN{cW:w MV:yOVY5OTN|NR?=
H9 Ml7DSpVv[3Srb36gRZN{[Xl? MV[xNFAhdk1? NGf4W|gzPCCq MlLNSG1UVw>? NWP5WolCTG:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMTDlfJBz\XO|aX;u MlzENlU3QDF|M{W=
HH NFznXGJHfW6ldHnvckBCe3OjeR?= Mn35NVAxKG6P MoH0NlQhcA>? MWrEUXNQ NVO5fWt3\G:5boLl[5Vt[XSnczDUS2Yu|rJzIHHu[EBKVC1zMjDlfJBz\XO|aX;u NGmxfVUzPTZ6MUOzOS=>
Hut-78 MVTNbYdz[XSrb36gRZN{[Xl? MWSxNFAhdk1? MXyyOEBp Mn;ySG1UVw>? MoHiVoVlfWOnczDj[YxtKG2rZ4LheIlwdiCkeTC4NQKBmzlyJR?= M2rMNVI2PjhzM{O1
HH MX7NbYdz[XSrb36gRZN{[Xl? MX:xNFAhdk1? NVHrfFVCOjRiaB?= MXHEUXNQ MWnS[YR2[2W|IHPlcIwhdWmpcnH0bY9vKGK7IEiw5qCUQTFn NUHTb3RiOjV4OEGzN|U>
U937 M13lbGZ2dmO2aX;uJGF{e2G7 MlXRNVAxKG6P M4DIUFYhcA>? NHLBeZBKdmS3Y3XzJGlNNThiZYjwdoV{e2mxbjDpckBNWFNvc4TpcZVt[XSnZDDVPVM4KG2jY4LvdIhi\2W| MXOyOVc6OTR5Nx?=
human PBMC NWTvVlFETnWwY4Tpc44hSXO|YYm= MlrpNVAxKG6P M2e2fFI1KGh? NYjmUoVKUW6mdXPld{BKVC16IILlcIVie2V? NEG0bpozPTd7MUS3Oy=>
ES6 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGP3eFJKSzVyPUCuNFAzOSCwTR?= NH\td2xUSU6JRWK=
SK-UT-1 NH;uPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nxOWlEPTB;MD6xOlMhdk1? MWXTRW5ITVJ?
SH-4 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe2PYx3UUN3ME2wMlE4OyCwTR?= Mm\jV2FPT0WU
TE-9 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzDTWM2OD1yLkG4NkBvVQ>? MkXKV2FPT0WU
A253 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHEO20{UUN3ME2wMlIxQCCwTR?= MlHsV2FPT0WU
no-10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ThfmlEPTB;MD6yNUBvVQ>? NUH1fogxW0GQR1XS
MMAC-SF NYnZfIhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jQUGlEPTB;MD6yNVYhdk1? NHXKPHlUSU6JRWK=
A101D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMkK1JI5O M4\1Z3NCVkeHUh?=
NTERA-S-cl-D1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTBwMkSzJI5O NXjjZolZW0GQR1XS
8-MG-BA NVPCc2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMkWgcm0> M4nSW3NCVkeHUh?=
KNS-42 MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMkW4JI5O MYDTRW5ITVJ?
LXF-289 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTBwMk[5JI5O MXHTRW5ITVJ?
OVCAR-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnyO41nUUN3ME2wMlI5QSCwTR?= M{X0SXNCVkeHUh?=
LOUCY MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLQTWM2OD1yLkK5N{BvVQ>? Mm\jV2FPT0WU
BB65-RCC NXHWOWFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3RTWM2OD1yLkOwOEBvVQ>? NGr2T5ZUSU6JRWK=
D-542MG NHGxNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwM{K5JI5O NWDTOWY6W0GQR1XS
ONS-76 M4PsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwM{Ogcm0> MUTTRW5ITVJ?
BB30-HNC M2i2Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITDfIFKSzVyPUCuN|M2KG6P NH;VWIRUSU6JRWK=
KS-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwM{Sgcm0> NW[xWXR1W0GQR1XS
A388 NHnIcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTwOJhFUUN3ME2wMlM2PiCwTR?= NWHaVFRCW0GQR1XS
ES8 M{Plfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;MTWM2OD1yLkSgcm0> M3nxVHNCVkeHUh?=
MZ2-MEL MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwNEC3JI5O NE\CbmpUSU6JRWK=
HCC2998 NXrlXYZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNEGyJI5O M4DrWXNCVkeHUh?=
D-247MG MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNEGzJI5O NGPHUIhUSU6JRWK=
ACN NXPpO|RTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrlXnlpUUN3ME2wMlQyPyCwTR?= MVLTRW5ITVJ?
LB2518-MEL NHLu[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHGRlhHUUN3ME2wMlQzPSCwTR?= MV\TRW5ITVJ?
ES1 NHXiSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNEOgcm0> M3r5RXNCVkeHUh?=
HCE-T MlK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwNEO5JI5O MVjTRW5ITVJ?
OS-RC-2 Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDxTWM2OD1yLkS0JI5O NUPx[JRXW0GQR1XS
MFH-ino NEDNeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTvdGVKSzVyPUCuOFQ{KG6P MV;TRW5ITVJ?
OCUB-M NUKxSYVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\2T5lKSzVyPUCuOFQ4KG6P MX3TRW5ITVJ?
CP66-MEL NYDPTmhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwNEezJI5O M3fOVnNCVkeHUh?=
LB771-HNC M1TaW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwNEe0JI5O Mon2V2FPT0WU
DSH1 NHvMXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrQ[21mUUN3ME2wMlQ5KG6P NHPMd3ZUSU6JRWK=
HUTU-80 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW[ye44xUUN3ME2wMlU{OyCwTR?= NWXTbZdkW0GQR1XS
CESS NYP3W5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3Dc3BRUUN3ME2wMlU{QCCwTR?= MXPTRW5ITVJ?
NCI-H747 M4nY[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLLTWM2OD1yLkWzPUBvVQ>? NX34NJhrW0GQR1XS
HT-144 NY[2XIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq1UIJKSzVyPUCuOVc3KG6P MnTiV2FPT0WU
COLO-829 M1vL[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNkG0JI5O MWDTRW5ITVJ?
A4-Fuk Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTBwNkKzJI5O Mn7OV2FPT0WU
GI-ME-N MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwNkO0JI5O M{HPb3NCVkeHUh?=
LB831-BLC NXrMOIFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnBfpoyUUN3ME2wMlY1OSCwTR?= NFrVb|hUSU6JRWK=
HOP-62 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\MdGlmUUN3ME2wMlY1PyCwTR?= NHvHRpVUSU6JRWK=
BB49-HNC M4TXe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjOTWM2OD1yLk[1NkBvVQ>? NHiyO2NUSU6JRWK=
D-336MG M3Wz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvtPZFKSzVyPUCuOlU4KG6P MXXTRW5ITVJ?
TK10 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTqTWM2OD1yLk[3PUBvVQ>? MVnTRW5ITVJ?
Ramos-2G6-4C10 NGLMcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13w[2lEPTB;MD62PVMhdk1? NED3bYNUSU6JRWK=
LB373-MEL-D NWThcVJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG[xSo5KSzVyPUCuO{BvVQ>? NFL1eWtUSU6JRWK=
SF126 NXuyUnFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTBwN{CxJI5O MlXRV2FPT0WU
UACC-257 M37mZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHHR3M2UUN3ME2wMlcyKG6P M3\hXHNCVkeHUh?=
KINGS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorxTWM2OD1yLkeyNkBvVQ>? NIPURXRUSU6JRWK=
LS-513 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nseWlEPTB;MD63N|khdk1? MX3TRW5ITVJ?
GI-1 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2H3VWlEPTB;MD63OlQhdk1? Mn;FV2FPT0WU
ES7 NXPURnA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfYTWM2OD1yLke2OkBvVQ>? NF:ycmJUSU6JRWK=
LB2241-RCC NWnsPWFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnCTWM2OD1yLkiwOEBvVQ>? Mlv0V2FPT0WU
D-263MG NXe1c2dmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTMVJhKSzVyPUCuPFA4KG6P NE\vdZZUSU6JRWK=
SW684 NYiyO|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;ERmZvUUN3ME2wMlgzOSCwTR?= MlHzV2FPT0WU
ML-2 M1jWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTBwOEKxJI5O MoXxV2FPT0WU
SK-LMS-1 NH3tSXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4nOeWlEPTB;MD64OVQhdk1? MWPTRW5ITVJ?
TE-5 M4DBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj4bFlKUUN3ME2wMlg3PSCwTR?= MXXTRW5ITVJ?
QIMR-WIL NF7H[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXSWW9KSzVyPUCuPFg6KG6P NUP6eGJ4W0GQR1XS
NCI-H1355 NF;XUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnLUW44UUN3ME2wMlg6PSCwTR?= MV7TRW5ITVJ?
SNB75 MmXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonlTWM2OD1yLkmxNkBvVQ>? NE\JZ3NUSU6JRWK=
RXF393 M17WNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\iTWM2OD1yLkmxOEBvVQ>? M{TUNnNCVkeHUh?=
IST-MEL1 NXzpVlFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL3cI5oUUN3ME2wMlkyPyCwTR?= NUXXe3loW0GQR1XS
SF268 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pUIh2UUN3ME2wMlkzOyCwTR?= MYDTRW5ITVJ?
KALS-1 M1PQS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O4[mlEPTB;MD65NlUhdk1? NWfh[WZyW0GQR1XS
HC-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1O4U2lEPTB;MD65O|Uhdk1? NIr6cWRUSU6JRWK=
SW872 NX[yWXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fhTWlEPTB;MD65PVYhdk1? M2ra[XNCVkeHUh?=
PSN1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlizTWM2OD1zLkCxJI5O NVnMUVhvW0GQR1XS
TE-1 NXLseY9oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\NTWM2OD1zLkCzJI5O MULTRW5ITVJ?
TE-10 NH7DW|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\XTWM2OD1zLkCzJI5O MmW3V2FPT0WU
RKO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3SXZpsUUN3ME2xMlA3KG6P MnnSV2FPT0WU
LC-2-ad NG\GSZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj2TWM2OD1zLkC4JI5O Mm\nV2FPT0WU
SK-MM-2 NX2x[FdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nEWmlEPTB;MT6wPUBvVQ>? NIPoO|hUSU6JRWK=
VA-ES-BJ NHPpbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTQVJVKSzVyPUGuNFkhdk1? M4PtOXNCVkeHUh?=
MZ7-mel M1rCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSxNJA1UUN3ME2xMlA6KG6P NXrhdJlYW0GQR1XS
D-392MG NH3xOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\RTWM2OD1zLkGgcm0> MmjSV2FPT0WU
CCRF-CEM M1;MdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmX2TWM2OD1zLkGzJI5O Ml\RV2FPT0WU
EM-2 NYnwUnN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHuTWM2OD1zLkG2JI5O MXHTRW5ITVJ?
HAL-01 NUXLUnZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHORphKSzVyPUGuNVghdk1? NF36[ldUSU6JRWK=
TE-8 NYThfnNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq3TodXUUN3ME2xMlE6KG6P NFjzfnFUSU6JRWK=
NCI-H1882 NXnqVoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TkOmlEPTB;MT6yJI5O MUXTRW5ITVJ?
Daudi MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{j2eWlEPTB;MT6yNkBvVQ>? MkjGV2FPT0WU
BL-41 NHfrd5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPsW49KSzVyPUGuNlUhdk1? NUTIb48yW0GQR1XS
SR NIn2U4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfUW5JKSzVyPUGuNlUhdk1? NUXvZ|lJW0GQR1XS
KM12 M4e4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LsZWlEPTB;MT6yO{BvVQ>? MWHTRW5ITVJ?
K5 M2qzV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwMkigcm0> MXvTRW5ITVJ?
A3-KAW MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm2VmoxUUN3ME2xMlI5KG6P M1j1VnNCVkeHUh?=
CMK M2HBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorDTWM2OD1zLkK5JI5O MYDTRW5ITVJ?
Calu-6 M4LmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFmz[ZFKSzVyPUGuNlkhdk1? M4fyfXNCVkeHUh?=
IST-SL2 M{PMVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT4TWM2OD1zLkOxJI5O NW\pcGE4W0GQR1XS
OPM-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HweGlEPTB;MT6zN{BvVQ>? NVrsfWh7W0GQR1XS
DU-4475 NUHGOodKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjJTWM2OD1zLkO2JI5O NFnRUVlUSU6JRWK=
ECC12 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwM{egcm0> M3zGUHNCVkeHUh?=
L-540 NVj3V4RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTFwM{egcm0> NVftflZ7W0GQR1XS
CAS-1 MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\Zb5RCUUN3ME2xMlM4KG6P NISzc5NUSU6JRWK=
PF-382 NVPyS2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn22TWM2OD1zLkS3JI5O MUTTRW5ITVJ?
LS-411N NH;YRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzHfFBKSzVyPUGuOVMhdk1? NX3ZdolnW0GQR1XS
NCI-H69 MoPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK5O5NtUUN3ME2xMlU1KG6P MofQV2FPT0WU
NB12 NVXLVpQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vOOmlEPTB;MT61OkBvVQ>? NWHlW|N5W0GQR1XS
HEL NYrCb3lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\jUpZKSzVyPUGuOlEhdk1? MmSwV2FPT0WU
GCIY NIHOdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\YeodKSzVyPUGuOlIhdk1? M4HQW3NCVkeHUh?=
EHEB M2m5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL3V2VnUUN3ME2xMlY4KG6P MofGV2FPT0WU
TGBC1TKB NF\lN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTmTWM2OD1zLkexJI5O MVHTRW5ITVJ?
KURAMOCHI MlTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr2cIRKSzVyPUGuO|Ihdk1? MlWyV2FPT0WU
U-266 M2Poe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwN{[gcm0> MYrTRW5ITVJ?
LC4-1 M4rIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPWTWM2OD1zLke5JI5O M{nDXnNCVkeHUh?=
NCI-H2126 NUOzZXpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\STWM2OD1zLkigcm0> Mm[4V2FPT0WU
NCI-H1092 NH7uSGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTFwODDuUS=> NIPteYpUSU6JRWK=
GB-1 M4PNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTEPZhKSzVyPUGuPFEhdk1? NU\GZ5hKW0GQR1XS
MV-4-11 MnPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmewTWM2OD1zLkiyJI5O NUT2V5hFW0GQR1XS
Becker M134T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfWTWM2OD1zLkizJI5O MVHTRW5ITVJ?
MPP-89 NYXzcHBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPRTWM2OD1zLki5JI5O M3vzU3NCVkeHUh?=
BE-13 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3yTWM2OD1zLkmzJI5O MV7TRW5ITVJ?
697 NFfQVG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP2RodKSzVyPUGuPVkhdk1? MYjTRW5ITVJ?
NKM-1 M122[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;2[HZIUUN3ME2yJI5O MX;TRW5ITVJ?
NB13 NH3XW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf5OXVKSzVyPUKgcm0> MVrTRW5ITVJ?
LS-123 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwMEKgcm0> M2XFN3NCVkeHUh?=
NB17 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTJwMESgcm0> MYHTRW5ITVJ?
LAN-6 NF;W[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTJwMEWgcm0> M4rqSnNCVkeHUh?=
EW-24 MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rNTmlEPTB;Mj6wPEBvVQ>? MVfTRW5ITVJ?
NOS-1 MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKxdY51UUN3ME2yMlEyKG6P MYLTRW5ITVJ?
BL-70 M3fZZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TZd2lEPTB;Mj6xNkBvVQ>? NV70TnpSW0GQR1XS
GT3TKB MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwMUKgcm0> M4XNR3NCVkeHUh?=
HH NYLBencxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rqN2lEPTB;Mj6xN{BvVQ>? M4LuNnNCVkeHUh?=
KE-37 NWfLVWhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJwMUOgcm0> NVLUe4dTW0GQR1XS
MOLT-4 NXz5XZpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\1WGlEPTB;Mj6xN{BvVQ>? M4S3NnNCVkeHUh?=
EKVX MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGzOoVKSzVyPUKuNVQhdk1? MkTZV2FPT0WU
KGN Mn\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXmTWM2OD1{LkG1JI5O NGPEW|VUSU6JRWK=
ES4 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTJwMU[gcm0> NVTySpdWW0GQR1XS
SJSA-1 NHzmS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu3SFFKSzVyPUKuNlEhdk1? MmHlV2FPT0WU
KMOE-2 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrOS4NKSzVyPUKuNlMhdk1? NXzOZmNWW0GQR1XS
NB5 NFn1dJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7OdpA6UUN3ME2yMlI4KG6P MlXVV2FPT0WU
BC-1 MnnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moj6TWM2OD1{LkOxJI5O M3K1PXNCVkeHUh?=
NB10 NV;1SINLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO3em1KSzVyPUKuN|Ihdk1? MnThV2FPT0WU
RPMI-8226 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvrTWM2OD1{LkO1JI5O MojyV2FPT0WU
SCC-3 NXnuWJN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4j0OWlEPTB;Mj6zO{BvVQ>? NUO0bGFuW0GQR1XS
ARH-77 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TnNWlEPTB;Mj6zPEBvVQ>? NHfpTJhUSU6JRWK=
NCI-H748 NFT2XHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTJwM{mgcm0> NEfJTllUSU6JRWK=
KU812 MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H6OmlEPTB;Mj60NkBvVQ>? NVm1UWp3W0GQR1XS
NCI-H64 M3[0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fzZWlEPTB;Mj60OEBvVQ>? NEPvbotUSU6JRWK=
NB69 NVnP[GVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7DTWM2OD1{LkS2JI5O NES2WoRUSU6JRWK=
KNS-81-FD NGfj[WJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfaUWpFUUN3ME2yMlQ5KG6P NUe1VIJSW0GQR1XS
LB1047-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv1R5lKSzVyPUKuOVchdk1? Mn3OV2FPT0WU
EB-3 M1qyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfTTWM2OD1{Lk[2JI5O NUPSZ4ZOW0GQR1XS
Mo-T MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLmTWM2OD1{Lke0JI5O M17WSXNCVkeHUh?=
EW-16 NYPmbXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Pv[2lEPTB;Mj63OUBvVQ>? MonxV2FPT0WU
CTV-1 NWfDXVlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\ae2lEPTB;Mj64JI5O NF;0PJhUSU6JRWK=
ETK-1 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTETWM2OD1{Lki0JI5O MUHTRW5ITVJ?
C2BBe1 M3jjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\yPHh2UUN3ME2yMlg6KG6P MYjTRW5ITVJ?
MOLT-16 MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJwOEmgcm0> NHi2V4ZUSU6JRWK=
SW954 MnLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnrTWM2OD1{Lkmgcm0> MVLTRW5ITVJ?
HT NFjl[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILqPYFKSzVyPUOuNFIhdk1? MnnRV2FPT0WU
KARPAS-299 M1\EOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTNwME[gcm0> M3P4fnNCVkeHUh?=
MONO-MAC-6 MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DvcWlEPTB;Mz6xJI5O MUfTRW5ITVJ?
CGTH-W-1 NH[xOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2j1cmlEPTB;Mz6xJI5O MXPTRW5ITVJ?
SK-PN-DW NUfCb41DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XRTmlEPTB;Mz6xOEBvVQ>? MmDZV2FPT0WU
CW-2 NW[wPGJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\DOWlEPTB;Mz6yNUBvVQ>? Mm\pV2FPT0WU
SK-N-DZ M1vxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXEeFc4UUN3ME2zMlI3KG6P NHy1NpRUSU6JRWK=
NEC8 M2Hw[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHMTWM2OD1|LkO1JI5O MknsV2FPT0WU
LB996-RCC M1T0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDDTWM2OD1|LkSgcm0> NIH3UnVUSU6JRWK=
DB NUGxRm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjud3M1UUN3ME2zMlQyKG6P MXfTRW5ITVJ?
TE-15 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULKNopmUUN3ME2zMlQ{KG6P M13KW3NCVkeHUh?=
COR-L88 NUn4fZlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHxd29KSzVyPUOuOFchdk1? MXvTRW5ITVJ?
LAMA-84 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33YOWlEPTB;Mz60PUBvVQ>? NWXxVIhFW0GQR1XS
MEG-01 M3vQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTNwNEmgcm0> Ml7CV2FPT0WU
LOXIMVI MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfJ[GxKSzVyPUOuOUBvVQ>? MVHTRW5ITVJ?
RPMI-8402 NYPGbFRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPkTnFsUUN3ME2zMlUhdk1? MVXTRW5ITVJ?
KARPAS-45 NYD6VXl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HN[mlEPTB;Mz61OEBvVQ>? M{CxXXNCVkeHUh?=
HCC1187 M{TnT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTNwNUSgcm0> Mny5V2FPT0WU
MZ1-PC MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfCXGxRUUN3ME2zMlU1KG6P NYPGTYlMW0GQR1XS
no-11 NFvGOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjmXFR1UUN3ME2zMlU2KG6P MU\TRW5ITVJ?
EVSA-T MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTNwNjDuUS=> MV7TRW5ITVJ?
DJM-1 M2PmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjsT4FZUUN3ME2zMlY{KG6P NXvZTlk1W0GQR1XS
COLO-684 MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nKXmlEPTB;Mz62OkBvVQ>? NX;lbJFJW0GQR1XS
NMC-G1 M1\ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNwNkigcm0> NHfrTY1USU6JRWK=
LC-1F NHjjXGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWX0[IV{UUN3ME2zMlc1KG6P NWjMemVNW0GQR1XS
RL95-2 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfZTWM2OD1|Lke5JI5O NVjyOFBSW0GQR1XS
COLO-320-HSR M{TMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDZNHl1UUN3ME2zMlkzKG6P Mk\UV2FPT0WU
RCC10RGB NYjFZ2FbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrlTWM2OD1|LkmzJI5O MoTVV2FPT0WU
HD-MY-Z NXPZZmM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH2[VFKSzVyPUOuPVMhdk1? MnXCV2FPT0WU
NCI-H2141 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DYSWlEPTB;ND6wOUBvVQ>? M3\0VHNCVkeHUh?=
K-562 NECydlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP5dYdKSzVyPUSuNVIhdk1? M4m3d3NCVkeHUh?=
NCI-H1648 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXmyNIJkUUN3ME20MlE{KG6P M2qxNHNCVkeHUh?=
OMC-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PDeWlEPTB;ND6xPEBvVQ>? NWjORVJuW0GQR1XS
LB647-SCLC NUHweXI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfTOYlzUUN3ME20MlIzKG6P MnPYV2FPT0WU
TE-12 NVXBblMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NViySFdRUUN3ME20MlI2KG6P NXTh[ZJ5W0GQR1XS
NOMO-1 M4Xyd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVn1PVBDUUN3ME20MlM{KG6P M3PGVnNCVkeHUh?=
Raji NHn2TWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfyVYNRUUN3ME20MlQ3KG6P NIfINWZUSU6JRWK=
NALM-6 M1eyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTRwNEmgcm0> Ml3xV2FPT0WU
HL-60 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwNkegcm0> MWjTRW5ITVJ?
IST-SL1 NWXrTG9bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fZdGlEPTB;ND62PEBvVQ>? NGTi[3VUSU6JRWK=
MHH-PREB-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOxNVh2UUN3ME20Mlg3KG6P M1v5Z3NCVkeHUh?=
MHH-NB-11 NXXkcphyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorhTWM2OD12LkmxJI5O Ml7UV2FPT0WU
JiyoyeP-2003 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHuyPJJKSzVyPUWgcm0> NGDSU4xUSU6JRWK=
SBC-1 NHn4TWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4K2VGlEPTB;NT6wNUBvVQ>? NUi3[lBSW0GQR1XS
CHP-126 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTVwME[gcm0> NV7L[XpiW0GQR1XS
LU-139 NIjBNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[xUZlKSzVyPUWuNVMhdk1? MYXTRW5ITVJ?
NCI-SNU-5 M2\oXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHITWM2OD13LkG3JI5O M3LXVHNCVkeHUh?=
SW962 MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTVwMkGgcm0> M3S4NXNCVkeHUh?=
EW-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rWRmlEPTB;NT6zNUBvVQ>? M1rTVnNCVkeHUh?=
NCI-H1417 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M132UGlEPTB;NT61NUBvVQ>? MUjTRW5ITVJ?
LU-65 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTVwOESgcm0> NHnLPZlUSU6JRWK=
D-502MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\jTWM2OD14LkO3JI5O MWfTRW5ITVJ?
BC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTyTWM2OD14Lk[xJI5O Ml;6V2FPT0WU
GDM-1 MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1e0[WlEPTB;Nj63O{BvVQ>? NXfnTnZXW0GQR1XS
NCI-H2196 NGHReGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\w[2lEPTB;Nj64JI5O NWi2WpV4W0GQR1XS
NB1 NVrQRYtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZwOEigcm0> MnT2V2FPT0WU
NCI-H345 MoPCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDIfotKSzVyPUeuNkBvVQ>? M13uR3NCVkeHUh?=
SU-DHL-1 NYnuXIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDTcXZKSzVyPUeuNlQhdk1? MkTDV2FPT0WU
JVM-2 MoDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV22[3dQUUN3ME23MlI5KG6P NYjRdG82W0GQR1XS
LU-134-A M{XlbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\pTWM2OD15LkO5JI5O NF\kXGJUSU6JRWK=
NCI-H1694 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmwTWM2OD15LkW4JI5O MmG3V2FPT0WU
NCI-SNU-16 NF\zVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XsbmlEPTB;Nz62OUBvVQ>? NGn0TVdUSU6JRWK=
L-363 NXvYSYhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHxNHpMUUN3ME23Mlchdk1? NX7IRXhtW0GQR1XS
KG-1 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTdwOUSgcm0> MkP5V2FPT0WU
MN-60 MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7rOVZDUUN3ME24MlE1KG6P MmLHV2FPT0WU
NB6 M3O1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jme2lEPTB;OD60PEBvVQ>? MkPVV2FPT0WU
MLMA NHXufFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHXXHRKSzVyPUiuPFUhdk1? M4DIR3NCVkeHUh?=
ATN-1 M2ThRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3POd2lEPTB;OD64PUBvVQ>? MWLTRW5ITVJ?
SK-NEP-1 M2DrTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfuOI45UUN3ME25MlAyKG6P NXjmUFBbW0GQR1XS
DMS-114 M2fZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nxVmlEPTB;OT62NkBvVQ>? MUTTRW5ITVJ?
CTB-1 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTlwNkegcm0> MXXTRW5ITVJ?
NCI-H2081 M1rWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLGNWF{UUN3ME2xNE4xQSCwTR?= MoTwV2FPT0WU
ES5 M1v3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7lbIl[UUN3ME2xNE4{QCCwTR?= NXL0c4VuW0GQR1XS
HCC1599 NUTrSGxJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\Ze4FFUUN3ME2xNU46OSCwTR?= M2TTe3NCVkeHUh?=
NCI-H23 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF{LkGyJI5O M4LPeXNCVkeHUh?=
NCI-H1581 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHrSZhKSzVyPUGyMlI5KG6P NIPTXmZUSU6JRWK=
JVM-3 NHr5fINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF{Lkm5JI5O MV\TRW5ITVJ?
NCI-SNU-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn3NXZKSzVyPUGzMlE6KG6P NYPXR5NVW0GQR1XS
NB7 Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7MTWM2OD1zNT65NkBvVQ>? M3nI[nNCVkeHUh?=
JAR MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn30TWM2OD1zNj6xN{BvVQ>? MofoV2FPT0WU
TGW Mor0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nR[2lEPTB;MU[uOFghdk1? MUXTRW5ITVJ?
U-87-MG MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;PTWM2OD1zNj63OkBvVQ>? MU\TRW5ITVJ?
NCI-H1436 M4C3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPSVJd4UUN3ME2xO{4xOSCwTR?= NYe5R4NPW0GQR1XS
GOTO M1H6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nESGlEPTB;MUeuNFYhdk1? M4S2[XNCVkeHUh?=
COLO-800 NIrhUnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG2cpR5UUN3ME2xO{43PCCwTR?= NIDocVlUSU6JRWK=
MFM-223 NF\XS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;MTXh7UUN3ME2xO{46OSCwTR?= MmnQV2FPT0WU
EW-18 NGS4TFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXKUYFKSzVyPUG3Mlk3KG6P M1TIUHNCVkeHUh?=
NB14 NV;KNGkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13DOWlEPTB;MUeuPVghdk1? NInPWYZUSU6JRWK=
EB2 M1j2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3ZTWM2OD1zOD6wPEBvVQ>? MYTTRW5ITVJ?
EoL-1- Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjkPIhTUUN3ME2xPE4{OSCwTR?= MX\TRW5ITVJ?
NCCIT NEPYWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vaR2lEPTB;MUiuN|Yhdk1? MYPTRW5ITVJ?
DG-75 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\mcHNKSzVyPUG4MlYyKG6P NInu[odUSU6JRWK=
HCC2218 MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzHcFFnUUN3ME2xPU42KG6P NFLFWFBUSU6JRWK=
TE-6 NFzsSZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PjUGlEPTB;MkCuNFghdk1? MnXZV2FPT0WU
SF539 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJyLk[3JI5O M4L6TXNCVkeHUh?=
NCI-H446 Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nRSmlEPTB;MkGuNVghdk1? Mnf0V2FPT0WU
IST-MES1 M2j2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS5TWM2OD1{Mj63O{BvVQ>? MWLTRW5ITVJ?
NCI-H82 NFvYOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KzSmlEPTB;MkOuNFIhdk1? MmTsV2FPT0WU
HCC2157 NI\tUIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[wb5NkUUN3ME2yN{4yOyCwTR?= M3XoUXNCVkeHUh?=
EW-12 NXS2SFV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELjfY5KSzVyPUKzMlE4KG6P MWDTRW5ITVJ?
SIMA M2iwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ|LkO4JI5O Mnj3V2FPT0WU
DOHH-2 NG[1RYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWj3NJl5UUN3ME2yN{41PSCwTR?= MXPTRW5ITVJ?
IM-9 NUPHfJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEL4NHJKSzVyPUKzMlU1KG6P NU\EWGNkW0GQR1XS
EC-GI-10 M{\kWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS5WWxtUUN3ME2yOE4zOyCwTR?= M{\rU3NCVkeHUh?=
HDLM-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfufFBKSzVyPUK0MlU1KG6P NGTFc|RUSU6JRWK=
LS-1034 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnMTVh7UUN3ME2yOU44PSCwTR?= M1nEUXNCVkeHUh?=
REH NHzqOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDsTWM2OD1{Nj60NUBvVQ>? M3G5[3NCVkeHUh?=
LU-165 M1;nXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPc2dKSzVyPUK2MlczKG6P MnHKV2FPT0WU
NH-12 NEO2eYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHJTWM2OD1{Nz62O{BvVQ>? MlTPV2FPT0WU
WSU-NHL NYHRVnlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrtTWM2OD1{OD6zPUBvVQ>? M37CVXNCVkeHUh?=
ECC4 M2fOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HWemlEPTB;MkiuO|khdk1? NHLQOo1USU6JRWK=
OCI-AML2 NUHqT|E{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TydmlEPTB;MkmuOlkhdk1? NULO[odpW0GQR1XS
EW-3 M4i4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTNyLkW5JI5O MVTTRW5ITVJ?
NCI-H526 NX3BNHNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUGzZo4yUUN3ME2zNk42PCCwTR?= MmiyV2FPT0WU
NCI-H719 NHrVcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTN2LkOxJI5O M1nvOXNCVkeHUh?=
KARPAS-422 M4TxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPPV|RCUUN3ME2zOU4xPCCwTR?= NGDqe3pUSU6JRWK=
SK-MEL-1 NYiyNnFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTN3LkG3JI5O NXGxblNwW0GQR1XS
ES3 MkTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\VTWM2OD1|NT6xPUBvVQ>? NXPYco0yW0GQR1XS
UACC-812 MmW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jnTmlEPTB;M{WuOFQhdk1? M2D1e3NCVkeHUh?=
C8166 NIC3[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLQTWM2OD1|NT63JI5O MonPV2FPT0WU
MDA-MB-134-VI MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknKTWM2OD1|NT64O{BvVQ>? MX3TRW5ITVJ?
D-283MED MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHNSmpKSzVyPUO3Mlc6KG6P NVfITG5sW0GQR1XS
SHP-77 NFTTRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT0VFR{UUN3ME2zPE4xOyCwTR?= MnP1V2FPT0WU
NCI-H2227 M{PBeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1joTmlEPTB;NECuOFkhdk1? NUfEUmFnW0GQR1XS
SKM-1 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrpTWM2OD12Mj62N{BvVQ>? MmX2V2FPT0WU
L-428 NFL4eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fINGlEPTB;NEOuPFYhdk1? NVq5d5BQW0GQR1XS
RPMI-6666 NIf6[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTR3Lki5JI5O MmH0V2FPT0WU
NCI-H716 NF[yToRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml31TWM2OD12OD64NUBvVQ>? Mn3pV2FPT0WU
DMS-79 NEmxR4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqzTWM2OD13MD63NUBvVQ>? MkH2V2FPT0WU
RS4-11 NGq2[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjmUWdOUUN3ME21NE45QCCwTR?= NVvrdpJKW0GQR1XS
NCI-H720 NGHac|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmeyTWM2OD13MT6xNUBvVQ>? M1OxZnNCVkeHUh?=
MC-CAR NYHkXI1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWwTGt7UUN3ME21NU42OiCwTR?= NIjF[mpUSU6JRWK=
TALL-1 NYXpXoxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HMUGlEPTB;NUOuPVEhdk1? MkX3V2FPT0WU
NCI-N87 M1PJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD5TWM2OD13ND6xPEBvVQ>? NHvmTGNUSU6JRWK=
P30-OHK NXPhbWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHJeWRqUUN3ME21OE43OSCwTR?= M3ftTHNCVkeHUh?=
LP-1 NVvHTXAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\6TWM2OD14MT6yPEBvVQ>? NXv1W4toW0GQR1XS
YT M2\4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LRNGlEPTB;NkGuPEBvVQ>? NWi4VZNGW0GQR1XS
MRK-nu-1 NGjrXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvNTpRrUUN3ME22NU45OiCwTR?= MXjTRW5ITVJ?
BT-474 M4TEdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnyb|VxUUN3ME22OUBvVQ>? NFnTRlhUSU6JRWK=
NCI-H322M NH3RR|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrtTWNKSzVyPU[2MlEyKG6P MUXTRW5ITVJ?
NCI-H128 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\qdppKSzVyPUe0Mlc4KG6P NHTieoZUSU6JRWK=
KMS-12-PE MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17oSmlEPTB;N{[uNlQhdk1? NXXLWotDW0GQR1XS
KP-N-YS NX7JT3hzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVf3b45OUUN3ME23Ok44PCCwTR?= NWrlNHlOW0GQR1XS
ALL-PO MkHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq3TWM2OD15Nz62OkBvVQ>? MUXTRW5ITVJ?
EW-13 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjyTWM2OD15Nz63OkBvVQ>? MUXTRW5ITVJ?
EW-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3leWhKSzVyPUe4MlUzKG6P NFHsbnpUSU6JRWK=
SK-N-FI MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7OTWM2OD16MD6yJI5O MVTTRW5ITVJ?
CAL-148 NFvJN5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYOGlEPTB;OEGuPFQhdk1? MkXKV2FPT0WU
RL NFzEfpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDDTWM2OD16Nj6wPUBvVQ>? MonDV2FPT0WU
AM-38 M3iwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO1fFdpUUN3ME24PE4xQCCwTR?= NWjjXVVEW0GQR1XS
RH-1 NFHmUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTl7Lki1JI5O MYrTRW5ITVJ?
NCI-H1770 MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFyMj60PUBvVQ>? M1Sy[HNCVkeHUh?=
SIG-M5 M1fJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDpflNKSzVyPUGwOU4xPiCwTR?= NHfvdotUSU6JRWK=
GR-ST MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFzMz6zOEBvVQ>? M1XOSHNCVkeHUh?=
ST486 M1XPbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrHOZpKSzVyPUGxOE4xPiCwTR?= MoLjV2FPT0WU
NCI-H1650 MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrN[3FKSzVyPUGxOU4zQSCwTR?= M3j3[nNCVkeHUh?=
MHH-CALL-2 M4PPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L3UGlEPTB;MUG1Mlchdk1? NXy5S3NyW0GQR1XS
BV-173 MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPR[IEyUUN3ME2xNlIvPzFibl2= MmjaV2FPT0WU
MC116 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHCUpZKSzVyPUG0PE45PSCwTR?= MkPNV2FPT0WU
NCI-H524 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\uTWM2OD1zNUmuNUBvVQ>? NWT5cHZNW0GQR1XS
SCLC-21H NVfCW49TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvLTWM2OD1zNUmuOFEhdk1? NIrsZ2xUSU6JRWK=
NCI-H1304 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rGN2lEPTB;MU[5MlIyKG6P M2SwenNCVkeHUh?=
NCI-H510A MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF6NT6zO{BvVQ>? NYLHe49kW0GQR1XS
NCI-H209 NI[3SVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DoWmlEPTB;MUm2MlUzKG6P NVH3UYQ5W0GQR1XS
KM-H2 MlPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTGTWM2OD1zOUeuNFUhdk1? M{fvbHNCVkeHUh?=
NCI-H1395 M4XuOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXqbmlKSzVyPUKxNE4yOyCwTR?= M3vRSXNCVkeHUh?=
NCI-H1155 M2XFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DGOWlEPTB;MkOwMlMzKG6P NV3jOHRRW0GQR1XS
COR-L279 NGDiSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH6O4VyUUN3ME2yOVIvOTdibl2= Mnq5V2FPT0WU
NCI-H1299 M2nFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjiTWM2OD1{NkGuO|Ehdk1? NU\EV5VyW0GQR1XS
EW-22 NWC4VHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rDXWlEPTB;Mk[zMlc2KG6P MmTaV2FPT0WU
SK-MEL-2 NEDMXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDtW2JMUUN3ME2yPFEvQSCwTR?= M3HBTXNCVkeHUh?=
KASUMI-1 NGLQT25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37LZmlEPTB;MkizMlA2KG6P MmDYV2FPT0WU
NCI-H187 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf1TWM2OD1{OEeuNFghdk1? M1vGN3NCVkeHUh?=
NCI-H2171 NFrucJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ6OD65NkBvVQ>? NULod4FIW0GQR1XS
LNCaP-Clone-FGC NF3DPXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjuPY9VUUN3ME2yPVUvOjZibl2= M2O4dXNCVkeHUh?=
NCI-H1522 Mnq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTNyNz6wOUBvVQ>? M{fQWXNCVkeHUh?=
SCH M4rYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\MTWM2OD1|MkKuNlIhdk1? NGfrblhUSU6JRWK=
THP-1 M3vDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPGNmJlUUN3ME2zNlIvPiCwTR?= NY\B[o43W0GQR1XS
SNU-C1 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTN4Mj6wPUBvVQ>? NUKyWnl6W0GQR1XS
CA46 NWrNVVRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fKe2lEPTB;M{ezMlY{KG6P MYPTRW5ITVJ?
NCI-H1963 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTN6Nj6xPUBvVQ>? MXTTRW5ITVJ?
DEL M37pV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN7MT6yO{BvVQ>? NHrDfW5USU6JRWK=
TUR MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjsRZFKSzVyPUO5Ok43OSCwTR?= NYHlWYRQW0GQR1XS
NCI-H226 NUTnXZZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\WeGxKUUN3ME20NFMvOjNibl2= NIfGNoVUSU6JRWK=
COLO-668 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDWcnNKSzVyPUSwN{42PyCwTR?= M{iyTHNCVkeHUh?=
CPC-N MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2WydGlEPTB;NECzMlc4KG6P M3vTfXNCVkeHUh?=
NCI-H889 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR4MT65NkBvVQ>? MV3TRW5ITVJ?
J-RT3-T3-5 M1ywcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGru[mVKSzVyPUWzNk42PyCwTR?= MYTTRW5ITVJ?
MSTO-211H NG\iOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDGSJQ4UUN3ME21O|QvOjZibl2= MXzTRW5ITVJ?
SCC-15 NGrrWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;ETWM2OD14NkeuOFchdk1? NXPGWFZbW0GQR1XS
SUP-T1 MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DDRWlEPTB;Nki2MlA1KG6P NFX4To1USU6JRWK=
DMS-153 NX\zeoNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXETWM2OD15NE[uPFMhdk1? NUDXbmZSW0GQR1XS
MS-1 NXHrNlNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPMTWM2OD15NUmuOFIhdk1? MlTGV2FPT0WU
TC-YIK M13GNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTd6MT6wNUBvVQ>? Mn32V2FPT0WU
RPMI-8866 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHpcoJyUUN3ME2xNFA3NjJ6IN88US=> MXvTRW5ITVJ?
KY821 NVLBOY1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jjfmlEPTB;MUCzOk4xPCEQvF2= NYH5cGhEW0GQR1XS
P31-FUJ MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3GU2xKUUN3ME2xNVEzNjd3IN88US=> NF\P[VdUSU6JRWK=
COLO-824 M1zKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Lh[GlEPTB;MUK2NU44QCEQvF2= NUSxSogzW0GQR1XS
U-698-M M{jGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJ{NkKuNVUh|ryP MmXmV2FPT0WU
TE-441-T MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTJ3MkGuO{DPxE1? M{C5dHNCVkeHUh?=
IMR-5 MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrmfXJKSzVyPUO0NFkvPjJizszN NXvYSmp3W0GQR1XS
NCI-H1838 NHTZSJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPkd3RKSzVyPUSxPFYvOzJizszN NX70[3pJW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo The anticancer effects of bortezomib as a single agent have been demonstrated in xenograft models of multiple myeloma, adult T-cell leukemia, lung, breast, prostate, pancreatic, head and neck, and colon cancer, and in melanoma. [2] Oral bortezomib 1.0 mg/ kg daily for 18 days causes tumor growth delays, as well as a decrease in the number of metastases in the Lewis lung cancer model. Bortezomib at a single dose of up to 5 mg/kg significantly decreased the surviving fraction of breast tumor cells. Bortezomib 1.0 mg/kg administrated weekly for 4 weeks reduces tumor growth by 60% in murine xenograft models of prostate cancer. 1.0 mg/kg Bortezomib administration for 4 weeks results in a 72% or 84% reduction in pancreatic cancer murine xenografts growth, as well as an increase in tumor cell apoptosis. 1.0 mg/kg Bortezomib treatment results in significant inhibition of human plasmacytoma xenograft growth, increase in tumor cells apoptosis and overall survival, and a decrease in tumor angiogenesis. [3]

Protocol

Kinase Assay
+ Expand

Kinetic Methods:

In a typical kinetic run, 2.00 mL of assay buffer (20 mM HEPES, 0.5 mM EDTA, 0.035% SDS, pH 7.8) and Suc-Leu-Leu-Val-Tyr-AMC in DMSO are added to a 3 mL fluorescence cuvette, and the cuvette is placed in the jacketed cell holder of a fluorescence spectrophotometer. Reaction temperature is maintained at 37℃ by a circulating water bath. After the reaction solution has reached thermal equilibrium (5 minutes), 1 μL−10 μL of the stock enzyme solution is added to the cuvette. Reaction progress is monitored by the increase in fluorescence emission at 440 nm (λex= 380 nm) that accompanies cleavage of AMC from peptide-AMC substrates.
Cell Research
+ Expand
  • Cell lines: Human multiple myeloma cells line U266
  • Concentrations: ~10 μM
  • Incubation Time: 2 days
  • Method:

    The inhibitory effect of Bortezomib on cell growth is assessed by measuring MTT dye absorbance of the cells. Cells from 48-hour cultures are pulsed with 10 μL of 5 mg/mL MTT to each well for the last 4 hour of 48-hour cultures, followed by 100 μL of isopropanol containing 0.04 N HCl. Absorbance is measured at 570 nm using a spectrophotometer.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Human plasmacytoma xenografts RPMI 8226
  • Formulation: Saline
  • Dosages: 1 mg/kg
  • Administration: i.v. twice weekly for 4 weeks, then once weekly
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (197.79 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.24
Formula

C19H25BN4O4

CAS No. 179324-69-7
Storage powder
in solvent
Synonyms LDP-341, MLM341

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02658396 Not yet recruiting Multiple Myeloma|Multiple Myeloma in Relapse|Refractory Multiple Myeloma Dana-Farber Cancer Institute|Genus Oncology, LLC|National Institutes of Health (NIH) December 2016 Phase 1
NCT02811978 Not yet recruiting Multiple Myeloma Janssen Research & Development, LLC September 2016 Phase 3
NCT02840539 Not yet recruiting Mantle Cell Lymphoma Seoul National University Hospital|Consortium for Improving Survival of Lymphoma August 2016 Phase 2
NCT02719613 Recruiting Multiple Myeloma Bristol-Myers Squibb|AbbVie July 2016 Phase 2
NCT02755597 Recruiting Relapsed/Refractory Multiple Myeloma AbbVie|Genentech, Inc. July 2016 Phase 3
NCT02718833 Recruiting Multiple Myeloma Massachusetts General Hospital|Celgene|Bristol-Myers Squibb June 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    On your website, it is mentioned that Bortezomib should be prepared at a concentration of 5 mg/ml in 2% DMSO/30% PEG300/ddH2O for in vivo use. But on the product sheet we received with the compound, it is mentioned: 5mg/ml in 0.5% methylcellulose, 0.2% tween 80. So which is the correct preparation buffer?

  • Answer:

    S1013 Bortezomib in 2% DMSO+30% PEG 300+ddH2O at 5 mg/ml is a clear solution, and it in 0.5% methylcellulose+0.2% Tween 80 is a suspension. Please choose the suitable vehicle according to your administration route. When you prepare the clear solution, please dissolve Bortezomib in DMSO first, make sure it dissolves well, warm it up to 45 degree and/or sonicate if necessary, then add PEG, mix well, and finally add water.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy Bortezomib (PS-341) | Bortezomib (PS-341) supplier | purchase Bortezomib (PS-341) | Bortezomib (PS-341) cost | Bortezomib (PS-341) manufacturer | order Bortezomib (PS-341) | Bortezomib (PS-341) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID